Qiagen NV (NYSE:QGEN) Shares Purchased by Bank of New York Mellon Corp

Share on StockTwits

Bank of New York Mellon Corp boosted its holdings in Qiagen NV (NYSE:QGEN) by 2.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,135,851 shares of the company’s stock after acquiring an additional 25,514 shares during the period. Bank of New York Mellon Corp owned 0.50% of Qiagen worth $47,251,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in QGEN. Lindbrook Capital LLC boosted its stake in shares of Qiagen by 57.0% during the 4th quarter. Lindbrook Capital LLC now owns 1,058 shares of the company’s stock worth $36,000 after purchasing an additional 384 shares during the last quarter. Procyon Private Wealth Partners LLC acquired a new stake in shares of Qiagen during the 4th quarter worth about $59,000. Signaturefd LLC boosted its stake in shares of Qiagen by 49.2% during the 4th quarter. Signaturefd LLC now owns 1,851 shares of the company’s stock worth $63,000 after purchasing an additional 610 shares during the last quarter. Huntington National Bank boosted its stake in shares of Qiagen by 21.0% during the 4th quarter. Huntington National Bank now owns 1,897 shares of the company’s stock worth $64,000 after purchasing an additional 329 shares during the last quarter. Finally, Exchange Traded Concepts LLC acquired a new stake in shares of Qiagen during the 4th quarter worth about $77,000. 68.67% of the stock is currently owned by institutional investors.

QGEN has been the topic of several analyst reports. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Qiagen in a research note on Thursday, February 6th. Barclays reiterated a “neutral” rating on shares of Qiagen in a report on Wednesday, February 5th. DZ Bank reiterated a “neutral” rating on shares of Qiagen in a report on Tuesday, March 3rd. Piper Sandler increased their price objective on shares of Qiagen from $29.00 to $36.00 and gave the stock a “neutral” rating in a report on Wednesday, February 5th. Finally, Berenberg Bank lowered shares of Qiagen from a “buy” rating to a “hold” rating in a report on Wednesday, March 4th. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating and seven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $37.54.

NYSE QGEN opened at $42.99 on Friday. Qiagen NV has a one year low of $25.04 and a one year high of $43.45. The company’s 50 day moving average price is $41.31 and its 200 day moving average price is $38.39. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.41 and a current ratio of 1.58. The firm has a market capitalization of $9.83 billion, a price-to-earnings ratio of -268.69, a PEG ratio of 2.06 and a beta of 0.31.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.34 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.27 by $0.07. Qiagen had a negative net margin of 2.01% and a positive return on equity of 13.80%. The firm had revenue of $372.10 million for the quarter, compared to analyst estimates of $342.71 million. During the same quarter last year, the firm posted $0.27 earnings per share. Qiagen’s revenue for the quarter was up 6.7% compared to the same quarter last year. Sell-side analysts forecast that Qiagen NV will post 1.7 EPS for the current fiscal year.

Qiagen Company Profile

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

Further Reading: What does a bar chart mean for investors?

Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen NV (NYSE:QGEN).

Institutional Ownership by Quarter for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Cloudera  Reaches New 12-Month High Following Better-Than-Expected Earnings
Cloudera Reaches New 12-Month High Following Better-Than-Expected Earnings
Horizon Therapeutics PLC  Insider Sells $2,857,317.10 in Stock
Horizon Therapeutics PLC Insider Sells $2,857,317.10 in Stock
ValuEngine Downgrades Cincinnati Bell  to Hold
ValuEngine Downgrades Cincinnati Bell to Hold
Insider Selling: AssetMark Financial Holdings  CEO Sells $329,339.52 in Stock
Insider Selling: AssetMark Financial Holdings CEO Sells $329,339.52 in Stock
Insider Selling: Slack  Director Sells $350,000.00 in Stock
Insider Selling: Slack Director Sells $350,000.00 in Stock
Insider Buying: Sutter Rock Capital Corp.  Major Shareholder Purchases $376,800.00 in Stock
Insider Buying: Sutter Rock Capital Corp. Major Shareholder Purchases $376,800.00 in Stock


 
© 2006-2020 Zolmax.